<DOC>
	<DOCNO>NCT01897233</DOCNO>
	<brief_summary>This Phase 3 , 2-part ( Part A Part B ) , open-label , multicenter study evaluate pharmacokinetics , safety , tolerability lumacaftor combination ivacaftor subject cystic fibrosis age 6 11 year F508del-mutation cystic fibrosis transmembrane conductance regulator ( CFTR ) gene .</brief_summary>
	<brief_title>Study Lumacaftor Combination With Ivacaftor Subjects 6 Through 11 Years Age With Cystic Fibrosis , Homozygous F508del-CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis CF define : 2 CFcausing mutation , chronic sinopulmonary disease gastrointestinal/nutritional abnormality Subjects weigh ≥15 kg without shoe Screening Visit Subjects homozygous F508delCFTR mutation Subjects percent predict forced expiratory volume 1 second ( FEV1 ) 70 % 105 % ( inclusive ) ( Part A ) ≥40 % ( Part B ) Screening Visit predict value adjust age , sex , height use Wang equation Subjects stable CF disease willing remain stable CF medication regimen Able swallow tablet History illness condition might confound result study pose additional risk administer study drug subject Acute respiratory infection , pulmonary exacerbation , change therapy pulmonary disease within 28 day Day 1 study Abnormal liver function define protocol Screening Visit Abnormal renal function define protocol Screening Visit History solid organ hematological transplantation Ongoing participation investigational drug study prior participation investigational drug study within 30 day prior Screening Visit History evidence lens opacity cataract Screening Visit Colonization organisms associate rapid decline pulmonary status Screening Visit ( Part A ) A standard 12lead ECG demonstrate QTcF &gt; 450 msec Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>